Literature DB >> 12829988

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.

Jay H Hoofnagle1, Marc G Ghany, David E Kleiner, Edward Doo, Theo Heller, Kittichai Promrat, Janus Ong, Farooq Khokhar, Alejandro Soza, David Herion, Yoon Park, James E Everhart, T Jake Liang.   

Abstract

To assess the efficacy and safety of maintenance therapy with ribavirin alone in chronic hepatitis C, 108 patients were treated with the combination of interferon alfa and ribavirin for 24 weeks; those who failed to have a virologic response were offered enrollment in a randomized, double-blind, controlled trial of ribavirin (1,000-1,200 mg daily) versus placebo for the subsequent 48 weeks. Patients were monitored at regular intervals with symptom questionnaires, serum aminotransferase levels, hepatitis C virus (HCV) RNA levels, and complete blood counts and underwent liver biopsy at the completion of therapy. Among 108 patients, 50 were still HCV RNA positive after 24 weeks of treatment, of whom 34 agreed to be randomized to continue either ribavirin monotherapy or placebo. Among 17 patients who received placebo, there was no overall improvement in symptoms, serum alanine aminotransferase (ALT) levels, HCV RNA levels, or hepatic histology. Among the 17 patients who received ribavirin, serum ALT levels and necroinflammatory features of liver histology were improved, whereas symptoms, HCV RNA levels, and hepatic fibrosis scores were not changed significantly from baseline. Responses to ribavirin seemed to be categorical, such that 8 patients (47%) had definite improvement in liver histology. Patients with improved histology had improvements in serum ALT levels both on combination therapy and after switching to ribavirin monotherapy. In conclusion, continuation of ribavirin monotherapy may maintain serum biochemical improvements that occur during interferon-ribavirin combination therapy in some patients and that these improvements are often associated with decreases in necroinflammatory changes in the liver. Whether these improvements will ultimately result in prevention of progression of hepatitis C requires further study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829988     DOI: 10.1053/jhep.2003.50258

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 2.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

3.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  The emergence of obsessive compulsive and compulsive buying symptomatology after acute stress and short-term use of ribavirin: case reports.

Authors:  Görkem Karakaş Uğurlu; Mustafa Uğurlu; Ali Cayköylü
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

5.  Comparison of the chronic effects of ribavirin and caffeic acid phenethyl ester (CAPE) on pancreatic damage and hepatotoxicity.

Authors:  Sedat Motor; Harun Alp; Serkan Senol; Neslihan Pınar; Vicdan Köksaldı Motor; Ibrahim Kaplan; Ayşe Alp; Cumali Gökçe
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Authors:  Eleanor Barnes; Mariolina Salio; Vincenzo Cerundolo; Joanne Medlin; Shona Murphy; Geoffrey Dusheiko; Paul Klenerman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Authors:  Eisuke Murakami; Michio Imamura; C Nelson Hayes; Hiromi Abe; Nobuhiko Hiraga; Yoji Honda; Atsushi Ono; Keiichi Kosaka; Tomokazu Kawaoka; Masataka Tsuge; Hiroshi Aikata; Shoichi Takahashi; Daiki Miki; Hidenori Ochi; Hirotaka Matsui; Akinori Kanai; Toshiya Inaba; Fiona McPhee; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

8.  Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.

Authors:  K K Snow; H L Bonkovsky; R J Fontana; H-Y Kim; R K Sterling; A M Di Bisceglie; T R Morgan; J L Dienstag; M G Ghany
Journal:  Aliment Pharmacol Ther       Date:  2010-01-12       Impact factor: 8.171

9.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Authors:  Jordan J Feld; Santosh Nanda; Ying Huang; Weiping Chen; Maggie Cam; Susan N Pusek; Lisa M Schweigler; Dickens Theodore; Steven L Zacks; T Jake Liang; Michael W Fried
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

10.  Amantadine therapy for chronic hepatitis C.

Authors:  Jill P Smith; Thomas R Riley; Attila Devenyi; Sandra I Bingaman; Allen Kunselman
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.